Legal settlements and loss contingencies:	9 Months Ended
Sep. 30, 2018
Legal settlements and loss contingencies:	NOTE 15 – Legal settlements and loss contingencies: In the third quarter of 2018, the Company recorded expenses of $19 million for legal settlements and loss contingencies, compared to income of $20 million in the third quarter of 2017. In the first nine months of 2018, Teva recorded income of $1,239 million in connection with legal settlements, compared to an expense of $324 million in the first nine months of 2017. The income in the first nine months of 2018 consisted primarily of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation. As of September 30, 2018 and December 31, 2017 Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $663 million and $1,232 million, respectively.

Legal settlements and loss contingencies:

9 Months Ended

Sep. 30, 2018

Legal settlements and loss contingencies:

NOTE 15 – Legal settlements and loss contingencies:

In the third quarter of 2018, the Company recorded expenses of $19 million for legal settlements and loss contingencies, compared to income of $20 million in the third quarter of 2017.

In the first nine months of 2018, Teva recorded income of $1,239 million in connection with legal settlements, compared to an expense of $324 million in the first nine months of 2017. The income in the first nine months of 2018 consisted primarily of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation.

As of September 30, 2018 and December 31, 2017 Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $663 million and $1,232 million, respectively.